TX-MARY-KAY-INC
11.3.2021 03:13:07 CET | Business Wire | Press release
Global beauty brand Mary Kay Inc., a leading corporate advocate of women’s entrepreneurship and empowerment, with its global headquarters in Addison, Texas, U.S.A, recently announced the appointment of Wendy Wang as President of its Asia Pacific Region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005138/en/
In her new role, Wang will provide strategic vision and leadership while working to create growth for the Company in the Asia Pacific region and beyond. Wang joined Mary Kay’s Corporate Legal Department in 2002 as Counsel for the Asia Pacific region. Shortly thereafter, she began a multi-year assignment in China. Upon her return to the global corporate headquarters in 2012, she was promoted to the position of Vice President and Associate General Counsel where she was responsible for legal work and compliance in all four regions. In 2019, Wang returned to China for a new assignment and was promoted to the position of Chief Commercial Officer for the Asia Pacific Region in 2020. In this role, she developed and drove the implementation of commercial strategies, and lead the Asia Pacific regional team in support of sales, marketing, business technology and operations, preparing her to take on the challenge of the Region President responsibilities.
“We want to congratulate Wendy as she transitions into her new role as President of Mary Kay Asia Pacific,” said David Holl, Mary Kay Chairman and Chief Executive Officer. “Wendy is passionate for the Mary Kay independent sales force and is a proven leader within Mary Kay. During her tenure, she has tirelessly built a strong and talented legal team that created a culture of compliance and compassion for China and the entire Asia Pacific Region. We are thrilled to welcome her as a member of the executive committee as we build on our efforts to enrich women’s lives around the globe.”
A graduate of The University of Texas at Austin, Wang earned her law degree as well as an undergraduate degree in Economics. She has received numerous honors and accolades including her recognition in 2017 by D CEO magazine as ‘Outstanding Deputy General Counsel/Associate General’ and the Greater Dallas Asian American Chamber of Commerce ‘Corporate Executive Diversity’ award.
“I am committed to empowering women and their families in the Asia Pacific region,” says Wang. “Supporting Mary Kay’s independent sales force is my greatest honor and always brings me hope, love and confidence in our future. We are a people business with a mission to enrich women’s lives and a vision to empower the Independent Beauty Consultant. My team and I are committed to delivering the very best business opportunity, building upon the values Mary Kay upholds as cornerstones of our corporate culture and mission.”
The promotion of Wang is the latest in Mary Kay Inc.’s decades-long commitment to empowering women to serve in leadership positions around the globe. Mary Kay is a company built by women for women, and that core value is reflected in Mary Kay’s global workforce gender diversity data (as of March 2021):
- 61% of Mary Kay’s global workforce is female
- 59% of Directors and above are female
- 54% of Global Vice Presidents and above are female
- Over 50% of Mary Kay’s global executive team is female
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop a rewarding opportunity for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay Inc. is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances which are sold exclusively by Mary Kay independent beauty consultants.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom